Titled, "Platforms of Hope: Advances in Gene Therapy and Gene Editing," the series is being created in collaboration with thought leaders from the National Center for Advancing Translational Sciences, the U.S. National Institute of Health Common Fund Somatic Cell Genome Editing program, and others.

At the end of 2021, the organization will publish a special report on gene therapy and gene editing innovation that will focus on efforts to accelerate the translation of discoveries into genetic medicines that benefit patients with rare diseases.

Cognate, Nucleus Biologics partner on cell, gene therapy media
Contract development and manufacturing organization Cognate BioServices and Nucleus Biologics have partnered to provide custom and commercial medias and...

FDA issues COVID-19 guidance for cell and gene therapy manufacturers
The U.S. Food and Drug Administration (FDA) published new guidance this week regarding manufacturing consideration for cell and gene therapy products...